Board of Directors
Edgardo “Ed” Baracchini, Ph.D.
Dr. Baracchini has over 25 years of experience in structuring and negotiating; research and development partnerships, mergers and acquisitions, and licensing agreements. To date, he has negotiated more than 80 business transactions with multinational and Asian pharmaceutical firms, biotechnology companies, and prominent universities, leading to transactions valued in excess of $5.3 billion. Additionally, Dr. Baracchini has been a key member of executive teams that have raised over $930 million in private and public financing and have successfully completed two IPOs.
Most recently, Dr. Baracchini was the Chief Business Officer at Imago Biosciences and he also provided consulting services in the areas of corporate and business development, investor relationship, and strategy advice to biotechnology companies since 2018. From 2010 to 2018 he served as the Chief Business Officer of Xencor, Inc. Prior to Xencor, he was Senior Vice President of Business Development at Metabasis Therapeutics form 2002 and until its merger with Ligand Pharmaceuticals in 2009. Dr. Baracchini held the position of Vice President of Business Development at Elitra Pharmaceuticals from 1999 to 2002. He served as the Director of Business Development at Agouron Pharmaceuticals from 1996 through its acquisition by Warner-Lambert in 1999. Dr. Baracchini was the Assistant Director of Business Development at Ionis Pharmaceuticals, from 1992 to 1996. From 1988 to 1992, Dr. Baracchini performed postdoctoral research at UCSD and The Scripps Research Institute.
Dr. Baracchini has extensive private and public company board experience with both USA based and international companies. He is currently on the Board of Directors of two public companies 4D Pharma, plc. (NASDAQ: LBPS) and INmune Bio, Inc. (NASDAQ: INMB), and is the Chairman of privately held CoImmune, Inc.
Dr. Baracchini holds a Ph.D. in molecular and cell biology from the University of Texas at Dallas, an M.B.A. from the University of California, Irvine, and a B.S. in microbiology from the University of Notre Dame.
Mr. Fekete is an advisor and board member for companies in the pharmaceutical, biotechnology and medical device industries. His areas of expertise include business strategy, capital markets, M&A and corporate governance developed through 35 years as an investment banker, independent advisor and board member for U.S. and international public and private companies.
Mr. Fekete currently serves as a board member for SeaSpine, Inc. (NASDAQ: SPNE), a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders, and a senior advisor for DFB Pharmaceuticals, a Texas based, private investment and development company focused on the formation and building of businesses in the pharmaceutical industry. Since 2010, Mr. Fekete has served as a board member for numerous other public and private pharmaceutical and medical device companies. He previously worked as an investment banker for Wells Fargo/Wachovia Securities, CIBC World Markets, Oppenheimer & Co., and L.F. Rothschild, Unterberg, Towbin. He obtained his B.S. in Business Administration from The Pennsylvania State University.
Gregory Tibbitts, C.P.A.
Mr. Tibbitts is a Certified Public Accountant (inactive) and has over 30 years of experience as a financial executive and a public accountant. His expertise includes addressing technical accounting issues, multiple public and private equity financings, complex operations, and direct interactions with the SEC on IPO and secondary offerings. He has worked as a Chief Financial Officer for both public and private companies and now operates a business advisory firm. He served as a board member for IDMI Pharma, Inc., a NASDAQ listed biotech company prior to its acquisition. He obtained a B.B.A. at University of San Diego and a M.B.A. at San Diego State University.
Lucio C. Rovati, M.D.
Dr. Rovati joined the Italy-based multinational pharmaceutical company Rottapharm in 1988 after a degree in Medicine and post-graduate specialization in Clinical Pharmacology at the University of Milano. After holding similar positions at the Universities of Naples and Parma, he became Professor of Clinical Pharmacology at the University of Milano-Bicocca, School of Medicine, where he is also Coordinator of a Master Course in Pharmaceutical Medicine.
After selling the commercial operations of Rottapharm in 2014 to other multinational pharmaceutical groups, Dr. Rovati founded and became Chief Executive Officer and Chief Scientific Officer of Rottapharm Biotech, a company entirely dedicated to the discovery and development of new innovative drugs, through which he contributes to the growth in the US and Europe of new biotechnology startups as an investor through his family holding Fidim, board member and scientific advisor.
Dr. Rovati is a member of several international scientific organizations, some of which collaborate with the Food and Drug Administration and the European Medicines Agency, to draft guidelines for drug development. Dr. Rovati has authored or co-authored over 185 full papers published in peer reviewed international scientific journals and 15 book chapters. Related scientific activity includes authorship of over 400 abstracts and selected/invited presentations in international congresses.
Jungwon Woo, Ph.D.
Dr. Woo has been the president of Genexine, Inc. since September 2020. She has worked at Genexine since 2013 as a clinical development and business development specialist. Prior to joining Genexine, Dr. Woo worked as a research associate in the Autoimmune Disease Research Department at St. Mary’s Hospital – Catholic University of Korea, as a senior research associate at Samsung Medical Center in Korea, and as a research associate at the College of Pharmacy, Seoul National University.
Dr. Woo obtained her B.S. in Pharmaceuticals at Seoul National University, M.S. in Microbial Pharmaceuticals at Seoul National University, and Ph.D. in Microbiology at Cornell University. She received her postdoctoral training at Harvard Medical School and at BioProcessing Technology Institute at the University of Minnesota.
Charles Nicolette, Ph.D.
Dr. Nicolette is the Chief Executive Officer of CoImmune, Inc. He has had a long career in the design, development and clinical testing of immune therapeutics targeting infectious diseases, cancer and inflammatory/autoimmune diseases. He is currently the chief executive officer and serves on the Board of Directors of CoImmune. For the 16 years preceding this position, he led the pre-clinical, translational and clinical development of technologies for Argos Therapeutics in various capacities including Vice President of Research and Development, Chief Scientific Officer and Chief Medical Officer. Prior to that he led the antigen discovery division of Genzyme Molecular Oncology for six years and is the inventor on dozens of patents. He received a Ph.D. in biochemistry and cellular and developmental biology from the State University of New York at Stony Brook, completing his doctoral dissertation and post-doctoral fellowship at Cold Spring Harbor Laboratory.